TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06573021

Intervention type: DRUG
Intervention: Near-infrared fluorescent cholangiography
Description: For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
Study: NCT06573190

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Liver Stiffness Measurement, Controlled Attenuation Parameter

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Guided Therapy
Study: NCT06572839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio-Maxx
Description: Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
Study: NCT06333626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-vitamin carbohydrate
Description: oral multi-vitamin carbohydrate beverage
Study: NCT05790434

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory test
Description: including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin

Intervention type: DIAGNOSTIC_TEST
Intervention: History taking and physical examination
Description: including fever, joint pain, local swelling and redness, sinus
Study: NCT05159726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: 12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
Study: NCT06159699

Intervention type: OTHER
Intervention: Online Survey
Description: The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
Study: NCT06075927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus specific T cells
Description: Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2
Study: NCT05790434

Intervention type: DIAGNOSTIC_TEST
Intervention: History taking and physical examination
Description: including fever, joint pain, local swelling and redness, sinus

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: including arthrocentesis culture，and frozen section

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: including arthrocentesis culture，and frozen section
Study: NCT04694196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentulous subjects
Description: Determine the occlusal plane using CN in anterior border of ramus
Study: NCT06192004

Intervention type: OTHER
Intervention: None (Observational Study)
Description: Not applicable since Observational Study
Study: NCT06663098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
Study: NCT06663709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRACE
Description: Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASK-oriented
Description: Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
Study: NCT06663397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Childbirth Preparation Training
Description: the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Childbirth Preparation Training
Description: the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
Study: NCT06662552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration using crazy fit machine
Description: It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field therapy
Description: EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
Study: NCT06663865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment
Study: NCT06561334

Intervention type: PROCEDURE
Intervention: Botulinum toxin injections
Description: Botulinum toxin injection to ease spasms of vocal cord
Study: NCT05825482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.
Description: Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.
Description: Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
Study: NCT05667298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Study: NCT05758740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health enhanced behavioural change intervention
Description: Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional behavioural change intervention
Description: Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
Study: NCT04467827

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: examining group
Description: Posture assessment in young healthy people depending on their level of physical activity
Study: NCT06163209

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Ultrasonography
Description: Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scan of the Face
Description: A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla
Study: NCT06351501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months
Description: 4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months
Description: 2 years of hormonal treatment from 16 to 18 years old.
Study: NCT05391607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperoncotic Albumin 20%
Description: Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isooncotic Albumin 5%
Description: Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate Crystalloid Solutions (control group)
Description: Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
Study: NCT06337344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Video Viewing
Description: The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
Study: NCT06124326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premenstrual Syndrome Supplement
Description: Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
Study: NCT06502730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment (COPE) Program
Description: It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
Study: NCT04257058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic educational material
Description: Electronic media via email
Study: NCT04466371

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
Study: NCT06420726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Supervised resistance exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: Supervised resistance exercise
Study: NCT05385510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™
Description: Adjuvanted malaria vaccine
Study: NCT00931905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic medication Plumbum metallicum
Description: The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydroalcoholic solution
Description: The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
Study: NCT06171165

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Swallow Protocol
Description: All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status.
Study: NCT04965597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04703465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: Tenofovir Alafenamide 25mg for 48 weeks will be delivered
Study: NCT04965597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study: NCT04589793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Style
Description: Life Style intervention including physical activity, diet, sleep and stress